Monogram gets HIV test boost on Pfizer's news
This article was originally published in Clinica
Executive Summary
Monogram Biosciences has moved closer to marketing its HIV test for predicting response to a new type of drug being developed by Pfizer, after the pharmaceutical was given a favourable recommendation for approval by US FDA advisors. The agency's antiviral drugs advisory committee voted unanimously (12-0) to recommend that the drug, maraviroc, be approved for use along with other antiretroviral agents for treatment-experienced adults infected with CCR5-tropic HIV-1. Although not bound by its advisors' recommendations, the FDA usually follows them.